A New Type of Medicine: Biotherapeutics Usher in a New Era

Bioprocessing

Bioprocessing and Capacity Trends: Growth Despite Continued Uncertainty

Cynthia A. Challener, Ph.D.

Pharma's Almanac

Nonviral Delivery

Can Nonviral Delivery Change the Economics of Gene Therapy?

David Alvaro, Ph.D.

Pharma's Almanac

Viral Vectors

Gene Therapy Manufacturing After the Capacity Boom

David Alvaro, Ph.D.

Pharma's Almanac

DS + DP Integration

Integrating Drug Substance and Drug Product to Reduce Risk Across Development

Dörthe Ackenhausen

IDT Biologika

Multi-Modality CDMO

The Rise of the Multi-Modality CDMO: Why Clients Need More Than Capacity

Kamal Preet

OneSource Specialty Pharma

DSP

Why More Product Upstream Creates New Pressure Downstream

Pharma's Almanac

Allogeneic CAR-T

Can Allogeneic Cell Therapy Solve the CAR-T Access Problem?

Pharma's Almanac

BsAbs in Oncology

Bispecific Antibodies Move Into the Heme-Onc Mainstream

David Alvaro, Ph.D.

Pharma's Almanac

Biosimilars

The Global Division of Labor Behind the Coming Oncology Biosimilar Wave

Pharma's Almanac

iPSCs

For iPSC Therapies, Manufacturing Consistency May Mean Preserving Function

Pharma's Almanac

Single-Use

The Changing Economics of Single-Use Biomanufacturing

Pharma's Almanac